NovoCure generates positive free cash flow despite GAAP losses and has beaten earnings estimates in 3 of the last 4 quarters, but quality metrics remain just below the minimum threshold and analysts project 49% upside that the current technicals do not yet support.
Thesis pillars
- Analyst Upside Target Gap↓Deteriorating
- Fcf Positive Despite Gaap Loss↓Deteriorating
- Earnings Beat Consistency↑Improving
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 26, 2026· older than 90 days
NovoCure Limited (NVCR) Stock Analysis
Range Bound setup · Inst Constrain edge
Healthcare · Medical Devices
Sell if holding. Engine safety override at $14.61: Quality below floor (3.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10 and A.R:R 3.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Below-average business quality; Below long-term trend.
NovoCure is a global oncology company that markets Tumor Treating Fields (TTFields) therapy through three FDA-approved devices: Optune Gio for glioblastoma, Optune Lua for non-small cell lung cancer and mesothelioma, and Optune Pax for pancreatic cancer. The company generates... Read more
Sell if holding. Engine safety override at $14.61: Quality below floor (3.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10 and A.R:R 3.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Below-average business quality; Below long-term trend. Chart setup: RSI 52 mid-range, Bollinger mid-band. Score 5.8/10, moderate confidence.
Passes 7/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 111d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
About NovoCure Limited
About NovoCure Limited
NovoCure markets three Tumor Treating Fields therapy devices, Optune Gio for glioblastoma, Optune Lua for non-small cell lung cancer and mesothelioma, and Optune Pax for pancreatic cancer, approved by the FDA in 2026, with the majority of revenue coming from Optune Gio sales in the United States, Germany, France and Japan. The company employed 217 sales force colleagues globally as of December 31, 2025, and submitted the final PMA module for a potential fourth indication, brain metastases from NSCLC under the proposed brand Optune Mya, in December 2025.
NovoCure bills payers a single monthly fee for TTFields therapy and bears the financial risk of collecting from third-party payers and patients directly in most markets, while distributing through hospitals in select countries such as Japan where the hospital receives government-mandated insurance reimbursement and contracts with NovoCure for equipment and services. As of December 31, 2025, the company had received national reimbursement for Optune Gio in nine countries including Germany, France and Japan, but had not yet secured national reimbursement for Optune Lua or Optune Pax in any active market. NovoCure has licensed Greater China commercialization rights for its products to Zai Lab under a 2018 agreement that also funds a multi-indication development partnership.
Show full overview
NovoCure's near-term financial results depend almost entirely on one product in one indication: the 10-K states that until the company secures additional regulatory approvals and reimbursement for Optune Lua and Optune Pax, almost all revenue will continue to derive from Optune Gio sales in newly diagnosed and recurrent glioblastoma. That concentration is compounded by U.S. drug-pricing policy exposure, as HHS's Medicare Drug Price Negotiation Program can select up to 20 products annually for mandated price reductions once they have been on the market at least seven years, a mechanism the filing flags as a risk to future per-unit reimbursement across its portfolio.
See also: Healthcare · Medical Devices
From NovoCure Limited's most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated Nov 1, 2026Recent Developments — NovoCure Limited
Latest news
- NEWS NovoCure Limited 12-Month Price Target Reduced to $21.33 — fiscal.ai Nov 1, 2026 negative
- NEWS Evercore ISI Group Maintains Outperform Rating on Novocure, Lowers Price Target — fiscal.ai Oct 31, 2026 positive
- NEWS Wells Fargo Maintains Equal-Weight on NovoCure, Lowers Price Target to $15 — benzinga Oct 30, 2026 negative
- NEWS Evercore ISI Group Maintains Outperform on NovoCure, Lowers Price Target to $20 — benzinga Oct 30, 2026 positive
- NEWS NovoCure Reports Q3 2026 Financial Results — fiscal.ai Oct 29, 2026 neutral
Latest item Nov 1, 2026 · Generated 2026-11-05T11:44:08Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductOptune Gio (glioblastoma)10-K Item 1A: 'almost all of our revenues will derive from sales and royalties from sales of Optune Gio for the treatment of newly diagnosed and recurrent GBM.'
- MEDIUMGeographicUnited States, Germany, France and Japan10-K Item 1: 'We market our Products in multiple countries around the globe with the majority of our revenues coming from the use of Optune Gio in the U.S., Germany, France and Japan.'
- MEDIUMcounterpartyZai Lab (Greater China license)10-K Item 1A: 'we have exclusively licensed rights to commercialize our Products in the field of oncology in Greater China to Zai pursuant to an agreement that also establishes a development partnership'
Material Events(8-K, last 90d)
- 2026-06-05Item 5.02LOWNovoCure's shareholders re-elected its full eleven-member board of directors at the June 3, 2026 annual meeting; a routine, uncontested election with no departures.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Unprofitable operations — net margin -16.8%. Quality floor flags this regardless of sector context.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $14.61: Quality below floor (3.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10 and A.R:R 3.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Below-average business quality; Below long-term trend. Chart setup: RSI 52 mid-range, Bollinger mid-band. Prior stop was $13.59. Score 5.8/10, moderate confidence.
Analyst target: $22.37 (+53.1% upside). Prior stop was $13.59. Stop-loss: $13.59.
Concentration risk — Product: Optune Gio (glioblastoma); Quality below floor (3.8 < 4.0).
NovoCure Limited trades at a P/E of N/A (forward -20.3). TrendMatrix value score: 8.9/10. Verdict: Sell.
13 analysts rate NVCR, with a consensus score of 3.9/5. 7 analysts publish price targets averaging $26.
What does NovoCure Limited do?NovoCure is a global oncology company that markets Tumor Treating Fields (TTFields) therapy through three FDA-approved...
NovoCure is a global oncology company that markets Tumor Treating Fields (TTFields) therapy through three FDA-approved devices: Optune Gio for glioblastoma, Optune Lua for non-small cell lung cancer and mesothelioma, and Optune Pax for pancreatic cancer. The company generates the majority of its revenue from Optune Gio sales in the U.S., Germany, France and Japan, and until further indications gain reimbursement and adoption, almost all revenue will continue to come from Optune Gio in glioblastoma; NovoCure has licensed Greater China commercialization rights to Zai Lab.